Effect of metformin on ECG, HR and BP of rats administered with cardiotoxic agent doxorubicin


  • Promise Madu Emeka Department of Pharmaceutical Sciences, College of Clinical Pharmacy, King Faisal University, Hofuf, Saudi Arabia
  • Anas Al-Ahmed Department of Pharmaceutical Sciences, College of Clinical Pharmacy, King Faisal University, Hofuf, Saudi Arabia




Blood pressure, Doxorubicin, ECG, Heart rate, Metformin, Rats


Background: Cardiovascular complications during drug therapy is worrisome and has been known to increase morbidity and mortality. The aim of this study was to investigate the effect of metformin on BP, HR, and ECG, after subacute administration of doxorubicin in rats.

Methods: Laboratory acclimatised animals were divided into 4 experimental groups consisting of group I as the control, given 0.5ml normal saline. Group II, received 3mg/kg doxorubicin on alternate days, while group III was given 300mg/kg metformin. The last group of animals were treated with 300mg/kg metformin, 30 min later, the animals were injected doxorubicin ip. The treatment lasted for 15 days thereafter, ECG, HR and BP were measured with anaesthesia.

Results: Result showed that doxorubicin induced ECG changes in terms of increased PR and QT intervals significantly. Whereas, QRS and RR intervals were at same time significantly decreased. Metformin was observed to significantly attenuate these changes. In addition, metformin restored decreases in HR that was caused by doxorubicin in a significant fashion. However, metformin alone produced a decrease in HR compared with control. The observed reduced SBP and DBP produced by doxorubicin were also alleviated by the administration of metformin. There were increases in BP parameters measured in normotensive rats with metformin alone.

Conclusions: In conclusion, metformin was found to attenuate doxorubicin-induced alteration in ECG pattern and restored the mechanical and physiological functions of the rat heart. Our data further suggests monitoring of CVS changes such as ECG particularly with drugs known to cause myocardial injury.



Coughlan KA, Valentine RJ, Ruderman NB, Saha AK. AMPK activation: a therapeutic target for type 2 diabetes? Diabetes Metab Syndr Obes. 2014;7:241-53.

Pecoraro M, Sorrentino R, Franceschelli S, Del Pizzo M, Pinto A, Popolo A. Doxorubicin-mediated cardiotoxicity: role of mitochondrial connexin 43. Cardiovasc Toxicol. 2015;15(4):366-76.

Soraya H, Khorrami A, Garjani A, Maleki-Dizaji N, Garjani A. Acute treatment with metformin improves cardiac function following isoproterenol induced myocardial infarction in rats. Pharmacol Rep. 2012;64(6):1476-84.

Wang S, Song P, Zou M-H. Inhibition of AMP-activated Protein Kinase α (AMPKα) by Doxorubicin Accentuates Genotoxic Stress and Cell Death in Mouse Embryonic Fibroblasts and Cardiomyocytes: role of p53 and sirt1. J Biol Chem. 2012;287(11):8001-12.

Gratia S, Kay L, Potenza L, Seffouh A, Novel-Chaté V, Schnebelen C, Sestili P, Schlattner U, Tokarska-Schlattner M. Inhibition of AMPK signalling by doxorubicin: at the crossroads of the cardiac responses to energetic, oxidative, and genotoxic stress. Cardiovasc Res. 2012;95(3):290-9.

Sasali A, Leahy JL. Is metformin cardioprotective? Diab Care. 2003;26 (1):243.

Abbasi F, Chu JW, McLaughlin T, Lamendola C, Leary ET, Reaven GM. Effect of metformin treatment on multiple cardiovascular disease risk factors in patients with type 2 diabetes mellitus. Metabolism. 2004;53:159-64.

Mistiaen WP. Effect of doxorubicin on cardiac Myocytes: update of the role of apoptosis, autophagy and other proteolytic pathways. Gavin J Oncol Res Ther. 2016;2016:14-23.

Deji N, Kume S, Araki S, Isshiki K, Araki H, Chin-Kanasaki M et al. Role of angiotensin II-mediated AMPK inactivation on obesity-related salt-sensitive hypertension. Biochem Biophys Res Commun. 2012;418(3):559-64.

Sung MM, Zordoky BN, Bujak AL, Lally JS, Fung D, Young ME et al. AMPK deficiency in cardiac muscle results in dilated cardiomyopathy in the absence of changes in energy metabolism. Cardiovasc Res. 2015;107(2):235-45.

Kobashigawa LC, Xu YC, Padbury JF, Tseng YT, Yano N. Metformin protects cardiomyocyte from doxorubicin induced cytotoxicity through an amp-activated protein kinase dependent signaling pathway: an in vitro study. PLOS ONE. 2014;9(8):e104888.

Ashour AE, Sayed-Ahmed MM, Abduallah AR, Korashy HM, Maayah ZH, Alkhalidi H et al. Metformin rescues the myocardium from doxorubicin-induced energy starvation and mitochondrial damage in rats. Oxid Med Cell Longev. 2012;2012:434195.

Salouege I, Ben Ali R, Ben Saïd D, Elkadri N, Kourda N, Lakhal M et al. Means of evaluation and protection from doxorubicin-induced cardiotoxicity and hepatotoxicity in rats. J Cancer Res Ther. 2014;10(2):274-8.

Kelleni MT, Amin EF, Abdelrahman AM. Effect of metformin and sitagliptin on doxorubicin-induced cardiotoxicity in rats: impact of oxidative stress, inflammation, and apoptosis. J Toxicol; 2015:424-813.

Saeed NM, El-Naga RN, El-Bakly WM, Abdel-Rahman HM, Salah ElDin RA, El-Demerdash E. Epigallocatechin-3-gallate pretreatment attenuates doxorubicin-induced cardiotoxicity in rats: A mechanistic study. Biochem Pharmacol. 2015;95(3):145-55.

De Francesco EM, Rocca C, Scavello F, Amelio D, Pasqua T, Rigiracciolo DC et al. Protective role of gper agonist g-1 on cardiotoxicity induced by doxorubicin. J Cell Physiol. 2016.

Galal A, El-Bakly WM, Al Haleem EN, El-Demerdash E. Selective A3 adenosine receptor agonist protects against doxorubicin‑induced cardiotoxicity. Cancer Chemother Pharmacol. 2016;77:309-22.

Hawley SA, Gadalla AE, Olsen GS, Hardie DG. The antidiabetic drug metformin activates the AMP-activated protein kinase cascade via an adenine nucleotide-independent mechanism. Diab. 2002;51(8):2420-5.

Dugan LL, You YH, Ali SS, Diamond-Stanic M, Miyamoto S, DeCleves AE et al. AMPK dysregulation promotes diabetes-related reduction of superoxide and mitochondrial function. J Clin Invest. 2013;123(11):4888-99.

Hur KY, Lee M-S. New mechanisms of metformin action: Focusing on mitochondria and the gut. J Diabetes Investig. 2015;6(6):600-9.

Aggarwal V, Dobrolet N, Fishberger S, Zablah J, Jayakar P, Ammous Z. PRKAG2 mutation: An easily missed cardiac specific non-lysosomal glycogenosis. Ann Pediatr Cardiol. 2015;8(2):153-6.

Koti BC, Nagathan S, Vishwanathswamy A, Gadad PC, Thippeswamy A. Cardioprotective effect of Vedic Guard against doxorubicin-induced cardiotoxicity in rats: A biochemical, electrocardiographic, and histopathological study. Pharmacogn Mag. 2013;9(34):176-81.

Temma K, Chugun A, Akera T, Kondo H, Kurebayashi N. Doxorubicin alters Ca2+ transients but fails to change Ca2+ sensitivity of contractile proteins. Environ Toxicol Pharmacol. 1996;1(2):131-9.

Hirano S, Agata N, Iguchi H, Tone H. Effects of pirarubicin in comparison with epirubicin and doxorubicin on the contractile function in rat isolated cardiac muscles. Gen Pharmacol. 1995;26(6):1339-47.

Hirano S, Wakazono K, Agata N, Iguchi H, Tone H. Comparison of cardiotoxicity of pirarubicin, epirubicin and doxorubicin in the rat. Drugs Exp Clin Res. 1994;20(4):153-60.

Jensen RA. Doxorubicin cardiotoxicity: contractile changes after long-term treatment in the rat. J Pharmacol Exp Ther. 1986;236(1):197-203.

Ozdoğan K, Taşkın E, Dursun N. Protective effect of carnosine on adriamycin-induced oxidative heart damage in rats. Anadolu Kardiyol Derg. 2011;11(1):3-10.

Tomczyk R, Ociepka A, Kiałka M, Milewicz T, Migacz K, Kowalczuk A et al. Metformin and changes in blood pressure and heart rate in lean patients with polycystic ovary syndrome (PCOS)-preliminary study. Przegl Lek. 2015;72(6):302-5.

Luque-Ramírez M, Mendieta-Azcona C, Alvarez-Blasco F, Escobar-Morreale HF. Effects of metformin versus ethinyl-estradiol plus cyproterone acetate on ambulatory blood pressure monitoring and carotid intima media thickness in women with the polycystic ovary syndrome. Fertil Steril. 2009;91(6):2527-36.

Huang X, Fan R, Lu Y, Yu C, Xu X, Zhang X, Liu P, Yan S, Chen C, Wang L. Regulatory effect of AMP-activated protein kinase on pulmonary hypertension induced by chronic hypoxia in rats: in vivo and in vitro studies. Mol Biol Rep. 2014;41(6):4031-41.

Sun M, Zhou G. An AMPK paradox in pulmonary arterial hypertension. Journal of Biomedical Science and Engineering. 2013;6(11):1085-9.

Turdi S, Fan X, Li J, Zhao J, Huff AF, Du M, Ren J. AMP-activated protein kinase deficiency exacerbates aging-induced myocardial contractile dysfunction. Aging Cell. 2010;9(4):592-606.

Saeedi R, Parsons HL, Wambolt RB, Paulson K, Sharma V, Dyck JR, Brownsey RW, Allard MF. Metabolic actions of metformin in the heart can occur by AMPK-independent mechanisms. Am J Physiol Heart Circ Physiol. 2008;294(6):H2497-506.




How to Cite

Emeka, P. M., & Al-Ahmed, A. (2017). Effect of metformin on ECG, HR and BP of rats administered with cardiotoxic agent doxorubicin. International Journal of Basic & Clinical Pharmacology, 6(5), 1054–1059. https://doi.org/10.18203/2319-2003.ijbcp20171656



Original Research Articles